Logo image of EPRX

EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EPRX - CA29842P1053 - Common Stock

8.175 USD
-0.02 (-0.3%)
Last: 1/13/2026, 10:48:24 AM
Fundamental Rating

3

Overall EPRX gets a fundamental rating of 3 out of 10. We evaluated EPRX against 528 industry peers in the Biotechnology industry. EPRX has a great financial health rating, but its profitability evaluates not so good. EPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPRX has reported negative net income.
In the past year EPRX has reported a negative cash flow from operations.
EPRX had negative earnings in each of the past 5 years.
In the past 5 years EPRX always reported negative operating cash flow.
EPRX Yearly Net Income VS EBIT VS OCF VS FCFEPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EPRX has a better Return On Assets (-31.81%) than 65.91% of its industry peers.
EPRX has a Return On Equity of -32.63%. This is in the better half of the industry: EPRX outperforms 74.43% of its industry peers.
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX Yearly ROA, ROE, ROICEPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX Yearly Profit, Operating, Gross MarginsEPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, EPRX has more shares outstanding
The number of shares outstanding for EPRX has been increased compared to 5 years ago.
EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX Yearly Shares OutstandingEPRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX Yearly Total Debt VS Total AssetsEPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 105.21 indicates that EPRX is not in any danger for bankruptcy at the moment.
EPRX has a better Altman-Z score (105.21) than 99.24% of its industry peers.
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 105.21
ROIC/WACCN/A
WACCN/A
EPRX Yearly LT Debt VS Equity VS FCFEPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 23.98. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
EPRX has a Current ratio of 23.98. This is amongst the best in the industry. EPRX outperforms 96.97% of its industry peers.
EPRX has a Quick Ratio of 23.98. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EPRX (23.98) is better than 96.97% of its industry peers.
Industry RankSector Rank
Current Ratio 23.98
Quick Ratio 23.98
EPRX Yearly Current Assets VS Current LiabilitesEPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EPRX have decreased by -6.65% in the last year.
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.78% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.44%
EPS Next 2Y12.24%
EPS Next 3Y17%
EPS Next 5Y10.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX Price Earnings VS Forward Price EarningsEPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX Per share dataEPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as EPRX's earnings are expected to grow with 17.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.24%
EPS Next 3Y17%

More info and screens

0

5. Dividend

5.1 Amount

EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (1/13/2026, 10:48:24 AM)

8.175

-0.02 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)N/A N/A
Inst Owners37.6%
Inst Owner ChangeN/A
Ins Owners17.49%
Ins Owner ChangeN/A
Market Cap414.06M
Revenue(TTM)N/A
Net Income(TTM)-29.37M
Analysts82.5
Price Target8.9 (8.87%)
Short Float %1.31%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.08%
Min EPS beat(2)-41.57%
Max EPS beat(2)-18.58%
EPS beat(4)0
Avg EPS beat(4)-41.02%
Min EPS beat(4)-80.04%
Max EPS beat(4)-18.58%
EPS beat(8)3
Avg EPS beat(8)-23.25%
EPS beat(12)7
Avg EPS beat(12)-9.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.13%
PT rev (3m)10.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.79%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.6
P/tB 4.6
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 214.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.98
Quick Ratio 23.98
Altman-Z 105.21
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
EPS Next Y18.44%
EPS Next 2Y12.24%
EPS Next 3Y17%
EPS Next 5Y10.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.36%
EBIT Next 3Y-2.11%
EBIT Next 5Y16.98%
FCF growth 1Y-0.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ

Can you provide the ChartMill fundamental rating for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.


What is the valuation status for EPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX). This can be considered as Overvalued.


Can you provide the profitability details for EUPRAXIA PHARMACEUTICALS INC?

EUPRAXIA PHARMACEUTICALS INC (EPRX) has a profitability rating of 1 / 10.


What is the expected EPS growth for EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

The Earnings per Share (EPS) of EUPRAXIA PHARMACEUTICALS INC (EPRX) is expected to grow by 18.44% in the next year.